PLYMOUTH MEETING , Pa., Jan. 8, 2013 /CNW/ - PRN Physician Recommended Nutriceuticals, a premier producer of condition-specific omega-3 products and macular vitamins, and Scope Ophthalmics, a leading distributor of innovative ophthalmic products in the UK, today announced the launch of Omega Eye in the United Kingdom and Ireland. The introduction of Omega Eye to the UK market is a significant enhancement to the treatments currently available for patients suffering from dry eye symptoms. The product offers a daily dose of 2668mg of omega-3 fatty acids in the re-esterified triglyceride form, including 1680mg of EPA and 560mg of DHA, as well as 1000 IU of Vitamin D.
With the current UK dry eye market estimated at 13MM units/annum, the market is growing at 12%/year. Experts say that this market will grow substantially in the coming years due to the aging population in the UK and also the environmental changes that can lead to dry eye symptoms. At present, 10% of the UK population suffers from some form of dry eye sensation. As a result, omega-3 supplementation, already proving its value as an essential part of dry eye therapy in the United States, is quickly becoming a topic of interest among UK ophthalmologists.
Kenneth Krieg, CEO of PRN Physician Recommended Nutriceuticals noted, "This product launch provides a tremendous opportunity to expand our reach in the rapidly growing UK market, and we are pleased to be collaborating with Scope Ophthalmics, a distributor that has such a strong reputation in the UK. We are also confident that with the prevalence of patients suffering from dry eye symptoms, the introduction of Omega Eye will offer significant benefits for PRN, Scope, ophthalmologists, and the patients they serve."
Tom Freyne, Commercial Director of Scope Ophthalmics, "Scope Ophthalmics is delighted to launch the PRN dry eye product (Omega Eye) in the UK. Our R&D team has been researching Omega-3 science for some time now and we really believe in this science as well as the science behind the PRN product. PRN's success with the dry eye product (Omega Eye) as well as their innovative business model, are the achievements that we all at Scope want to replicate in the UK. We are also very excited by the range of products that PRN offers as well as their focus on clinical literature of the highest standard. PRN's plan to conduct product specific studies with some of the most respected names in ophthalmology in the US has been another milestone and reason for our enthusiasm with this partnership. We look forward to working with the incredible team in PRN and growing with them and their new products in the future."
The launch of Omega Eye will be supported by a 10-person sales force as well as a dedicated Health Coach, providing additional support to physicians' offices.
About PRN Physician Recommended Nutriceuticals
PRN is a leading developer of condition-specific omega-3 products and nutritional supplements. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity. Recently acknowledged on the Inc. 500|5000 list of fastest growing privately held companies, PRN has demonstrated three-year revenue growth of 375%.
About Scope Ophthalmics
Scope Ophthalmics is a private limited company with offices in Manchester & London in the UK and also an office just outside Dublin, Ireland. The company targets consultant ophthalmologists in the NHS and private hospitals and has established very strong relationships with top corneal and external eye disease doctors, providing a platform to launch any new innovative products.
SOURCE: PRN Physician Recommended Nutriceuticals
For further information:
Stefan Schoen, Vice President, Business Development, +1-610-862-0182